PDL BioPharma Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
145.4 M |
Public Float |
148.12 M |
PDL BioPharma Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.42 |
Market Cap |
$372.11 M |
Shares Outstanding |
119.65 M |
Public Float |
143.25 M |
Address |
932 Southwood Boulevard Incline Village Nevada 89451 United States |
Employees | - |
Website | http://www.pdl.com |
Updated | 07/08/2019 |
PDL BioPharma, Inc. produces and markets biopharmaceutical products. It operates through the following segments: Income Generating Assets, Pharmaceutical, and Medical Devices. The Income Generating Assets segment consists of revenues derived from notes and other long-term receivables, royalty rights-at fair value, equity investments, and royalties from issued patents in the United States and elsewhere. |